A Phase 1, First-in-Human Study of MEN2312, a KAT6 inhibitor, as Monotherapy and in Combination in Participants with Advanced Breast Cancer

2024-514661-19-01 Protocol MEN2312-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 18 Feb 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 8 sites · Protocol MEN2312-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 286
Countries 1
Sites 8

Advanced ER+/HER2- Breast Cancer

Key facts

Sponsor
Stemline Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
18 Feb 2026 → ongoing
Decision date (initial)
2025-12-29
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514661-19-01
WHO UTN
U1111-1308-5349
ClinicalTrials.gov
NCT06638307

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Advanced ER+/HER2- Breast Cancer

VersionLevelCodeTermSystem organ class
24.0 PT 10085481 Hormone receptor positive HER2 negative breast cancer 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Stemline Therapeutics Inc.

Sponsor organisation
Stemline Therapeutics Inc.
Address
750 Lexington Avenue
City
New York
Postcode
10022-1200
Country
United States

Scientific contact point

Organisation
Stemline Therapeutics Inc.
Contact name
Clinical Development and Clinical Operations

Public contact point

Organisation
Stemline Therapeutics Inc.
Contact name
Clinical Development and Clinical Operations

Locations

1 EU/EEA country · 8 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ongoing, recruiting 46 8
Rest of world
United States, United Kingdom
240

Investigational sites

Spain

8 sites · Ongoing, recruiting
Hospital Universitario 12 De Octubre
03408: Oncología Médica, Avenida De Cordoba Sn, 28041, Madrid
Hospital Universitario Y Politecnico La Fe
03407:Oncología Médica, Avenida Fernando Abril Martorell 106, 46026, Valencia
Hospital Clinico San Carlos
03406:Oncología Médica, Calle Del Profesor Martin Lagos Sn, 28040, Madrid
Hospital Beata Maria Ana
#03403 :Oncología medica, Calle Del Doctor Esquerdo No. 83, 28007, Madrid
Hospital Universitario Hm Sanchinarro
#03401: START, Calle Ona 10, 28050, Madrid
Hospital Clinico Universitario De Valencia
03405:Oncologia Médica y Hematologia, Avenida Blasco Ibanez 17, 46010, Valencia
Hospital Universitari Vall D Hebron
03404:Oncología medica, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital Universitario Fundacion Jimenez Diaz
#03402 :Oncología, Avenida De Los Reyes Catolicos 2, 28040, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2026-02-18 2026-03-04

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-09-12 Spain Acceptable
2025-12-26
2025-12-29